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sonnel and patient time. Assessments at a single time point may
under- or overestimate the time required to perform related
activities. In this study, we use data from a large clinical trial of
exercise therapy in patients with heart failure to evaluate whether
there is evidence of a learning curve with regard to time spent on
non-exercise activities across 36 supervised exercise training ses-
sions across 12 weeks. METHODS: As part of the economic
evaluation planned alongside the NIH-sponsored HF-ACTION
trial, a Provider and Patient Time Assessment Survey was admin-
istered across 9 study sites representing a subset of 56 patients.
The survey was designed to assess provider time with and
without the patient, pre- and post-exercise, to account for a
variety of related tasks (e.g. pulling charts, patient education,
scheduling, etc.). Linear growth models were used to model the
trajectory change of time spent on ‘non-exercise’ activities across
36 visits. RESULTS: Data were available for 39 (69.6%) patients
who completed all 36 exercise sessions, 7 (12.5%) patients who
were still enrolled in ongoing exercise training, and 10 (17.9%)
patients who discontinued exercise training. The average non-
exercise time associated with supervised training was 30.3
(SD = 19.8) minutes, comprised of 20.6 minutes spent with
patients and 9.5 minutes without patients. After adjusting for
whether warm-up/cool-down activities were included, the total
time spent on non-exercise activities decreased signiﬁcantly
(parameter estimate: -1.04 minutes/week; p = 0.007), with
approximately equal reductions in time with patients (-0.57
minutes/week; p = 0.038), and without patients (-0.65 minutes/
week; p = 0.058) over 12 weeks. CONCLUSION: Our analysis
suggests that providers and patients experienced efﬁciency gains
in regard to time spent on activities associated with supervised
exercise training. These results demonstrate the potential impor-
tance of comprehensive time assessment when evaluating disease
management programs.
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OBJECTIVE: The goal of the study was to test the effects of
step therapy on pharmaceutical and medical utilization and
costs. This study examined the effect of step therapy for anti-
depressant and antihypertensive medications. METHODS: The
data was extracted from the MarketScan database, representing
the health care experience of enrollees in employer-sponsored,
commercial health plans. The sample consisted of employees
and dependents of 4 employers (2-step therapy and 2 controls)
who were continuously enrolled in the MarketScan database
from 2003 through the third quarter of 2006 and who used
antidepressants (N = 15,552 step therapy; N = 45,244 control)
or antihypertensives (N = 11,851 step therapy; N = 30,822
control) at least once during the study period. An analytic ﬁle
was created using a panel data framework, yielding 15 obser-
vations or quarters of data per patient. Chi-square and Stu-
dent’s t-tests were computed to compare demographic and
clinical characteristics as well as outcome variables between the
step therapy and comparison groups after step therapy had been
implemented for plans with step therapy. Multivariate general-
ized estimating equation (GEE) models were used to estimate
the effects of step therapy on spending and utilization while
controlling for important covariates and adjusting for clustering
by patient. RESULTS: Step therapy had the intended effect of
increasing generic prescribing and lowering brand prescribing.
Overall, medication costs were reduced in the step therapy plans
in the initial period following implementation. However, inpa-
tient, outpatient, and emergency room utilization and costs
were higher in the step therapy plans after step therapy was
implemented relative to the comparison groups. Medication
discontinuation rates for the targeted drugs increased in step
therapy plans. CONCLUSION: Implementation of step therapy
produces intended and unintended results. The intended results
of reducing drug costs are found to co-occur with unintended
results that may adversely affect patients as evidenced by higher
ER and inpatient utilization.
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OBJECTIVE: In this study, cost-effectiveness of different doses
of Atorvastatin, Pravastatin, Rosuvastatin and Simvastatin are
compared. The results are used to evaluate if prescription deci-
sions follow willingness to pay. METHODS: Incremental cost-
effectiveness ratios (ICERs) were calculated using a model to be
published in Value in Health. However, for this analysis, we used
efﬁcacy estimates from a meta-analysis that compared several
statins across dose ranges. Furthermore, we considered two sce-
narios. In scenario 1, doses are doubled after 12 weeks of treat-
ment if the LDL level is over 115 mg/dL; in scenario 2, the dose
is ﬁxed. For the analysis of prescription patterns and costs per
dose, we used ofﬁcial data. RESULTS: Results show that, in both
scenarios, Pravastatin 10 mg and 20 mg and Atorvastatin 10 mg
are dominated. Taking Simvastatin 10 mg as reference, the ICER
of Simvastatin 20 mg in scenario 1 is €203,780 and the ICER of
Rosuvastatin 10 mg is €108,293, while the ICER of Rosuvastatin
10 mg compared to Simvastatin 20 mg is €61,670. In scenario 2,
the ICERs of Simvastatin 20 mg and Rosuvastatin 10 mg are
€199.933 and €61.238, respectively, while Rosuvastatin 10 mg
dominates Simvastatin 20 mg. In both cases the Simvastatin
20 mg ICER is well above the €50.000 per life year gained
threshold. However, Simvastatin 20 mg is the most prescribed
alternative in Portugal. In fact, during 2006 its market share was
around 66%, while Simvastatin 10 mg accounted just for 2%
and Rosuvastatin 10 mg for 12%. Future research will show how
results change with the market launch of Rosuvastatin 5 mg.
CONCLUSION: Doctors are not inﬂuenced by economic evalu-
ation when prescribing statins. Results show that Simvastatin
10 mg should be used as ﬁrst line and Rosuvastatin 10 mg as
second line strategies. Most probably, the high market share of
Simvastatin 20 mg reﬂects the “ﬁrst mover” advantage in the
market.
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OBJECTIVE: To evaluate the effectiveness of a patient- and
physician-directed communication program to consider initia-
tion of statin therapy among diabetics. METHODS: Educa-
tional letters were sent to physicians and patients from a large
commercial health plan. Physician- and patient-directed letters
were sent to 593 and 579 patients respectively. Letters to the
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